Purespring Therapeutics

Purespring Therapeutics

Biotechnology Research

We are Purespring. We are on a mission to radically transform the treatment of kidney diseases.

About us

Purespring, which launched in November 2020 with £45 million of funding from Syncona Ltd, is the first company to be directly targeting the podocyte, a specialized kidney cell implicated in many kidney diseases, through AAV gene therapy. This approach is based on the work of Professor Moin Saleem, Professor of Paediatric Renal Medicine at the University of Bristol, where he heads a world leading group researching glomerular diseases.

Industry
Biotechnology Research
Company size
11-50 employees
Headquarters
London
Type
Privately Held
Founded
2020
Specialties
biotechnology, gene therapy, and kidney diseases

Locations

  • Primary

    2 Royal College Street

    The London Bioscience Innovation Centre

    London, NW1 0NH, GB

    Get directions

Employees at Purespring Therapeutics

Updates

Similar pages

Browse jobs

Funding